HomeCompareEKDHF vs SBUX

EKDHF vs SBUX: Dividend Comparison 2026

EKDHF yields 588.53% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKDHF wins by $278.8K in total portfolio value
10 years
EKDHF
EKDHF
● Live price
588.53%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436.3K
Annual income
$1,271.11
Full EKDHF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — EKDHF vs SBUX

📍 EKDHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKDHFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKDHF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKDHF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKDHF
Annual income on $10K today (after 15% tax)
$50,025.01/yr
After 10yr DRIP, annual income (after tax)
$1,080.44/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $54,883.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKDHF + SBUX for your $10,000?

EKDHF: 50%SBUX: 50%
100% SBUX50/50100% EKDHF
Portfolio after 10yr
$296.9K
Annual income
$33,555.61/yr
Blended yield
11.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

EKDHF
No analyst data
Altman Z
9.2
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKDHF buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKDHFSBUX
Forward yield588.53%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%48.3%
Portfolio after 10y$436.3K$157.5K
Annual income after 10y$1,271.11$65,840.13
Total dividends collected$267.1K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: EKDHF vs SBUX ($10,000, DRIP)

YearEKDHF PortfolioEKDHF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$40,126$29,426.48$11,107$407.21+$29.0KEKDHF
2$98,112$55,176.68$12,512$626.87+$85.6KEKDHF
3$168,022$63,042.42$14,366$978.69+$153.7KEKDHF
4$230,234$50,450.31$16,929$1,557.50+$213.3KEKDHF
5$278,654$32,303.75$20,658$2,543.80+$258.0KEKDHF
6$316,430$18,269.86$26,406$4,302.22+$290.0KEKDHF
7$348,275$9,694.67$35,877$7,622.00+$312.4KEKDHF
8$377,640$4,986.13$52,741$14,352.64+$324.9KEKDHF
9$406,601$2,526.42$85,676$29,243.03+$320.9KEKDHF
10$436,334$1,271.11$157,513$65,840.13+$278.8KEKDHF

EKDHF vs SBUX: Complete Analysis 2026

EKDHFStock

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Full EKDHF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this EKDHF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKDHF vs SCHDEKDHF vs JEPIEKDHF vs OEKDHF vs KOEKDHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.